Angiotensin III (human, mouse): A Core RAAS Peptide for Cardiovascular and Neuroendocrine Research

Executive Summary: Angiotensin III (human, mouse) is a biologically active hexapeptide produced by N-terminal cleavage of angiotensin II, central to renin-angiotensin-aldosterone system (RAAS) signaling (Oliveira et al., 2025). It mediates approximately 40% of angiotensin II’s pressor activity and retains full aldosterone-stimulating capability (ApexBio, A1043). The peptide acts on both AT1 and AT2 receptor subtypes, with relative specificity for AT2, and is highly soluble in water, ethanol, and DMSO. Studies in rodents confirm its utility in cardiovascular and neuroendocrine models, and its role in modulating viral receptor interactions is emerging. Proper storage and handling are critical to maintain its bioactivity and stability.

Biological Rationale

Angiotensin III (sequence: Arg-Val-Tyr-Ile-His-Pro-Phe) is generated from angiotensin II by aminopeptidase A-mediated N-terminal cleavage in erythrocytes and tissues (Oliveira et al., 2025). It is an integral component of the RAAS, which regulates blood pressure, fluid balance, and electrolyte homeostasis. Unlike angiotensin II, Angiotensin III demonstrates selectivity for AT2 receptors, though it also binds AT1. Its presence is essential for full RAAS cascade functionality, contributing to both rapid pressor responses and sustained aldosterone secretion. Exogenous administration in animal models induces predictable cardiovascular and endocrine effects, making it a reference molecule for dissecting RAAS mechanisms (Angiotensin III: A Versatile Peptide for Cardiovascular Research—this article extends these findings with quantitative solubility and receptor data).

Mechanism of Action of Angiotensin III (human, mouse)

Angiotensin III exerts its effects through high-affinity binding to AT1 and AT2 receptors, both of which are G protein-coupled receptors (GPCRs) widespread in cardiovascular, renal, and neural tissues (Oliveira et al., 2025). Upon receptor engagement:

• It mediates vasoconstriction and pressor activity, accounting for ~40% of angiotensin II’s effect.
• Angiotensin III fully stimulates aldosterone secretion from the adrenal cortex, paralleling angiotensin II.
• It suppresses renin release, providing negative feedback within the RAAS.
• AT2 receptor activation by Angiotensin III is associated with vasodilatory, anti-fibrotic, and anti-inflammatory actions, counterbalancing AT1-mediated vasoconstriction.

In neuroendocrine contexts, Angiotensin III induces dipsogenic and pressor responses in rodent brain models. Its activity is modulated by the presence of aminopeptidases and receptor expression profiles in target tissues. The peptide’s molecular weight is 931.09 Da, and its chemical formula is C₄₆H₆₆N₁₂O₉. Solubility is ≥23.2 mg/mL in water, ≥43.8 mg/mL in ethanol, and ≥93.1 mg/mL in DMSO (ApexBio, A1043).

Evidence & Benchmarks

• Angiotensin III mediates 40% of the pressor response attributed to angiotensin II in vivo (Oliveira et al., 2025).
• It retains full aldosterone-stimulating capacity in isolated adrenal preparations (Oliveira et al., 2025).
• Angiotensin III exhibits high aqueous and organic solubility, enabling use at ≥93.1 mg/mL in DMSO without precipitation (ApexBio, A1043).
• In rodent brain microinjection models, it reliably elicits both pressor and dipsogenic responses, confirming neuroendocrine activity (Angiotensin III: The Essential Peptide for RAAS and Cardiovascular Disease Models—this article updates with emerging viral pathogenesis links).
• Shorter angiotensin peptides, including Angiotensin III (2–8), enhance the binding of SARS-CoV-2 spike protein to AXL, implicating them in viral pathogenesis (Oliveira et al., 2025).
• For optimal stability, the peptide should be stored desiccated at -20°C; long-term solution storage leads to degradation (ApexBio, A1043).

Applications, Limits & Misconceptions

Angiotensin III is extensively used in:

• Cardiovascular research models to dissect RAAS-mediated blood pressure regulation.
• Neuroendocrine signaling studies, especially those investigating thirst and hormone secretion.
• Pathogenesis assays exploring SARS-CoV-2 spike protein binding to host cell receptors (Oliveira et al., 2025).
• Comparative receptor pharmacology, given its distinct AT1/AT2 binding profile compared to angiotensin II and IV (Angiotensin III (human, mouse): Unraveling RAAS Peptide Dynamics—this article clarifies advanced receptor signaling mechanisms).

Common Pitfalls or Misconceptions

• Angiotensin III does not fully recapitulate all angiotensin II-mediated cardiovascular effects—pressor potency is lower.
• Long-term storage in solution at >4°C rapidly degrades activity; always store desiccated at -20°C.
• It is not suitable for modeling angiotensin I–mediated pathways, as it lacks the N-terminal aspartate and arginine residues.
• Angiotensin III’s effects in viral pathogenesis are emerging but not yet fully characterized in human infection models.
• It should not be assumed to have identical pharmacokinetics in humans and rodents without direct evidence.

Workflow Integration & Parameters

Angiotensin III (human, mouse) is supplied as a solid and should be reconstituted in water, ethanol, or DMSO immediately prior to use. Its high solubility (≥93.1 mg/mL in DMSO) supports a wide range of experimental concentrations. For cardiovascular assays, typical working concentrations range from 1 nM to 1 μM, depending on tissue and model system. Solutions must be filtered and used fresh to prevent peptide oxidation or hydrolysis. Desiccated storage at -20°C is essential; avoid freeze-thaw cycles. For detailed protocol integration, see Angiotensin III: A Versatile RAAS Peptide for Advanced Cardiovascular Models—this article extends with specific storage and solubility guidance.

Conclusion & Outlook

Angiotensin III (human, mouse) is a critical tool for precision modeling of RAAS physiology, uniquely combining high solubility, dual receptor targeting, and robust aldosterone-stimulating activity. Its application spans cardiovascular, neuroendocrine, and now viral pathogenesis research. Researchers should observe strict handling and storage parameters to maintain activity. Ongoing studies will further elucidate its roles in human disease and receptor pharmacology (ApexBio, A1043).